Education
About Us
Working with TipRanks
Follow Us
Entrada Therapeutics Inc (TRDA)
NASDAQ:TRDA
RESEARCH TOOLSreports
TRDA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$7.10 - $21.79
Previous CloseN/A
Volume35.15K
Average Volume (3M)143.18K
Market Cap
$297.00M
Enterprise Value$383.55M
Total Cash (Recent Filing)$101.21M
Total Debt (Recent Filing)$59.21M
Price to Earnings (P/E)4.1
Beta1.66
Next Earnings
May 08, 2025EPS Estimate
-0.79Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.91
Shares Outstanding37,594,630
10 Day Avg. Volume208,772
30 Day Avg. Volume143,181
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.87
Price to Cash Flow (P/CF)-3.10
P/FCF Ratio0.00
Enterprise Value/Market Cap1.29
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.82
Enterprise Value/Ebitda7.84
Forecast
1Y Price Target
$24.33Price Target Upside207.97% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Entrada Therapeutics Inc News
PremiumCompany Announcements
Entrada Therapeutics Gains UK Approval for DMD Study
PremiumCompany Announcements
Entrada Therapeutics Reports Strong 2024 Financial Results
---
Bulls Say, Bears Say
Bulls Say
Clinical AdvancementsEntrada's ENTR-601-45 entering the clinic puts the asset as first-in-class for the next-gen exon skippers with what is believed to be a best-in-class preclinical dataset.
Regulatory ApprovalsFDA has lifted the clinical hold on ENTR-601-44 and provided authorization to initiate ELEVATE-44-102, a Phase 1b multiple ascending dose (MAD) clinical study.
Strategic PartnershipsCollaboration with Vertex for VX-670 (ENTR-701) in DM1 is progressing, with the therapy moving into the MAD portion of trials.
Bears Say
Trial DelaysThe delay in trial commencement will ensure that adult patients enrolling in the Phase Ib study have immediate access to continuous ENTR-601-44 therapy through the OLE rather than experiencing a material off-treatment gap.
---
Ownership Overview
40.54% Insiders
14.31% Mutual Funds
2.75% Other Institutional Investors
34.01% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TRDA FAQ
What was Entrada Therapeutics Inc’s price range in the past 12 months?
Entrada Therapeutics Inc lowest stock price was $7.10 and its highest was $21.79 in the past 12 months.
What is Entrada Therapeutics Inc’s market cap?
Entrada Therapeutics Inc’s market cap is $297.00M.
When is Entrada Therapeutics Inc’s upcoming earnings report date?
Entrada Therapeutics Inc’s upcoming earnings report date is May 08, 2025 which is in 24 days.
How were Entrada Therapeutics Inc’s earnings last quarter?
Entrada Therapeutics Inc released its earnings results on Feb 27, 2025. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of -$0.67 by $0.7.
Is Entrada Therapeutics Inc overvalued?
According to Wall Street analysts Entrada Therapeutics Inc’s price is currently Undervalued.
Does Entrada Therapeutics Inc pay dividends?
Entrada Therapeutics Inc does not currently pay dividends.
What is Entrada Therapeutics Inc’s EPS estimate?
Entrada Therapeutics Inc’s EPS estimate is -0.79.
How many shares outstanding does Entrada Therapeutics Inc have?
Entrada Therapeutics Inc has 37,594,630 shares outstanding.
What happened to Entrada Therapeutics Inc’s price movement after its last earnings report?
Entrada Therapeutics Inc reported an EPS of $0.03 in its last earnings report, beating expectations of -$0.67. Following the earnings report the stock price went down -0.333%.
Which hedge fund is a major shareholder of Entrada Therapeutics Inc?
Currently, no hedge funds are holding shares in TRDA
---
Entrada Therapeutics Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.33 (207.97% Upside)
$24.33 (207.97% Upside)
Blogger Sentiment
Bullish
TRDA Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 70.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.5%
Last 30 Days ▲ 10.9%
Last 30 Days ▲ 10.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.42%
12-Months-Change
Fundamentals
Return on Equity
19.56%
Trailing 12-Months
Asset Growth
12.18%
Trailing 12-Months
Company Description
Entrada Therapeutics Inc
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
---
TRDA Stock 12 Month Forecast
Average Price Target
$24.33
▲(207.97% Upside)
Technical Analysis
Rigel
―
Benitec Biopharma
―
Allogene Therapeutics
―
Amylyx Pharmaceuticals Inc
―
Zenas BioPharma, Inc.
―
Best Analysts Covering TRDA
1 Year
1 Year Success Rate
2/7 ratings generated profit
1 Year Average Return
-15.99%
reiterated a buy rating 20 days ago
Copying Boobalan Pachaiyappan's trades and holding each position for 1 Year would result in 28.57% of your transactions generating a profit, with an average return of -15.99% per trade.
---